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To the Editor: 1 
 2 
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) by Dr Lippman and 3 
colleagues1 reported that selenium or vitamin E alone or in combination did not prevent prostate 4 
cancer. The negative results of this trial confirm the outcomes in the Nutritional Prevention of 5 
Cancer (NPC) Trial for those participants with the highest baseline plasma selenium 6 
concentration prior to supplementation with selenized yeast.2 The conclusion from both NPC and 7 
SELECT is that daily selenium supplementation will not benefit all persons.  Cancer risk 8 
reduction with selenium should be expected only in men with low or suboptimal levels prior to 9 
supplementation.  10 
 11 
That the relationship between selenium intake and cancer risk may follow a U-shaped dose-12 
response, as suggested by studies in dogs3, is consistent with the results of SELECT and NPC.   13 
At baseline, the average participant in SELECT had selenium status within the trough of the U-14 
shaped curve, i.e., not low or suboptimal.  After supplementation with 200 g/d selenium as 15 
selenomethionine, the average SELECT participant achieved selenium levels that far exceeded 16 
the high post-supplementation values of men in NPC in the highest baseline-selenium tertile.  17 
Those NPC participants experienced no prostate-cancer risk reduction and an almost 3-fold 18 
increased incidence of diabetes2,4.  In SELECT, there was no reduction in prostate-cancer risk 19 
and a statistically nonsignificant increased diabetes incidence.  We therefore consider the results 20 
of SELECT and NPC to be consistent, not contradictory.  21 
 22 
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We believe that it is time to move beyond the belief that any particular agent administered at the 23 
same dose to all participants will benefit the overall population and instead attempt to 24 
individualize cancer prevention3. Subsets of individuals should be identified who are more likely 25 
to benefit from supplementation, such as persons with low selenium concentrations or who have 26 
the particular selenoprotein-P genotype that has recently been found to affect prostate-cancer 27 
risk5.  This stance is distinct from claiming that we know which types of cancer will or will not 28 
be prevented by selenium. 29 
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